Sartorius Stedim Biotech Past Earnings Performance

Past criteria checks 1/6

Sartorius Stedim Biotech has been growing earnings at an average annual rate of 5.4%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been growing at an average rate of 13.6% per year. Sartorius Stedim Biotech's return on equity is 4.2%, and it has net margins of 5.9%.

Key information

5.4%

Earnings growth rate

5.3%

EPS growth rate

Life Sciences Industry Growth	26.8%
Revenue growth rate	13.6%
Return on equity	4.2%
Net Margin	5.9%
Next Earnings Update	28 Jan 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Sartorius Stedim Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XTRA:56S1 Revenue, expenses and earnings (EUR Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Sep 24	2,736	161	641	143
30 Jun 24	2,747	170	636	134
31 Mar 24	2,716	255	625	129
31 Dec 23	2,776	310	618	130
30 Sep 23	2,959	460	598	131
30 Jun 23	3,170	635	619	132
31 Mar 23	3,356	717	604	135
31 Dec 22	3,493	876	612	132
30 Sep 22	3,381	681	605	125
30 Jun 22	3,259	625	577	123
31 Mar 22	3,094	559	564	119
31 Dec 21	2,887	414	532	111
30 Sep 21	2,639	523	479	103
30 Jun 21	2,393	469	450	98
31 Mar 21	2,143	398	417	89
31 Dec 20	1,910	336	392	84
30 Sep 20	1,743	299	373	84
30 Jun 20	1,600	255	353	81
31 Mar 20	1,520	254	334	81
31 Dec 19	1,441	235	318	79
30 Sep 19	1,393	247	308	68
30 Jun 19	1,336	238	301	65
31 Mar 19	1,274	223	293	61
31 Dec 18	1,212	208	283	61
30 Sep 18	1,172	185	277	60
30 Jun 18	1,121	173	264	59
31 Mar 18	1,093	162	259	57
31 Dec 17	1,081	161	258	53
30 Sep 17	1,073	151	252	53
30 Jun 17	1,089	157	255	50
31 Mar 17	1,075	157	250	49
31 Dec 16	1,052	154	244	48
30 Sep 16	1,009	145	242	47
30 Jun 16	971	142	234	46
31 Mar 16	926	136	226	43
31 Dec 15	884	118	217	42
30 Sep 15	850	111	207	43
30 Jun 15	781	89	197	35
31 Mar 15	734	76	189	39
31 Dec 14	684	72	184	34
30 Sep 14	646	71	173	39
30 Jun 14	620	67	168	39
31 Mar 14	604	68	165	38
31 Dec 13	588	66	159	36

Quality Earnings: 56S1 has a large one-off gain of €59.6M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 56S1's current net profit margins (5.9%) are lower than last year (15.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 56S1's earnings have grown by 5.4% per year over the past 5 years.

Accelerating Growth: 56S1's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 56S1 had negative earnings growth (-65.1%) over the past year, making it difficult to compare to the Life Sciences industry average (-1.4%).

Return on Equity

High ROE: 56S1's Return on Equity (4.2%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/18 18:47
End of Day Share Price	2024/12/18 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sartorius Stedim Biotech S.A. is covered by 31 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Stéphan Dubosq	Arkeon Finance
Charles Pitman-King	Barclays
Scott Bardo	Berenberg